منابع مشابه
Pembrolizumab
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types...
متن کاملAnti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes.
A 44-year-old Caucasian woman with no diabetic history was admitted to the emergency department in 2014 for vomiting and confusion, with polyuria, polydipsia, and a very recent weight loss (15 days). Biological tests revealed severe hyperglycemia and diabetic ketoacidosis (glycemia 50.45 mmol/L, ketones 31, pH 7.25, HCO3 2 3mEq/L), with acute renal failure (39 mL/min/1.73 m) and elevated serum ...
متن کاملPembrolizumab reactivates pulmonary granulomatosis
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or their therapies. Immunotherapy has gained a lot of interest in the past few years and has recently gained approval as first line therapy in multiple advanced stage malignancies. Pneumonitis has been described as complication of such therapy. Granulomatous inflammation has been only rarely report...
متن کاملAutoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
The utility of immunotherapy, such as pembrolizumab, is becoming essential in the treatment of certain cancers. Pembrolizumab works through binding of programmed cell death 1 receptor that blocks the binding of the programmed cell death ligand 1 and is commonly used in non-small cell lung cancer and melanoma. Pembrolizumab has been reported to be associated with multiple adverse reactions such ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endokrynologia Polska
سال: 2021
ISSN: 2299-8306,0423-104X
DOI: 10.5603/ep.a2021.0053